ClinicalTrials.gg
CompletedNCT03148483IMPROVEUpdated Aug 3, 2021

Calcium-vitamin D & Periodontal Therapy for Improving Metabolic and Inflammatory Profile Among Pregnant Women

An interventional study of Early PT and Delayed PT in Periodontitis and Inflammation, sponsored by University of Westminster. Completed at 1 site in Brazil. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-03.

Sponsored by University of Westminster · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Periodontitis with a site in Brazil — 7 open to participants now, 12 under way, 1 of them phase 3. Periodontitis · Brazil.

Enrollment
17th of 45
70 · median 56
Started
2017
with 2 others
No phase
27 of 48
5 open now
Registered
17th of 48
by date

Among the 48 studies in Periodontitis with a site in Brazil, this one is the 17th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2017, is one of 27 with no phase, and was the 17th registered.

Periodontitis

1,242 studies on the registry are indexed under Periodontitis; 304 are open to participants now.

Browse Periodontitis studies →

Open to participants now

7 of the 48 studies in Periodontitis with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 163 Periodontitis studies recruiting now, 80 (49%) set no upper age limit and 62 (38%) stop at 75 or younger; 12 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 49 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Periodontitis with a site in Brazil, or all of them as a file.
02

Study summary

The improvement of maternal and child health remains a key issue in global health. Production and improved accessibility of healthy and nutrient-rich milk-based products could potentially tackle health and nutrition inequalities in low-income countries.

This study will assess the acceptability of a multi-component intervention, including provision of calcium/vitamin-D fortified milk and periodontal therapy (PT), for improving maternal periodontal health and metabolic and inflammatory profiles. The IMPROVE trial is a feasibility randomised controlled trial (RCT) with parallel qualitative process evaluation. The target population is low-income, pregnant, Brazilian women, with periodontitis, who have not seen a dentist in the last 6 months. A series of focus group discussions and interviews with the target population will be conducted to identify key barriers and enablers to adoption and implementation of the intervention in prenatal clinics in Rio de Janeiro/Brazil. Participants will be allocated to 4 groups: 1) early PT (during pregnancy) plus fortified milk; 2) early PT plus plain milk; 3) delayed PT (after delivery) plus fortified milk; 4) delayed PT plus plain milk.

The final results will contribute to the understanding of the significance of calcium and vitamin D for short and long-term health and the occurrence of diseases, as well as to inform the current global debate on vitamin-D supplementation and fortification policy.

03

Conditions studied

  • Periodontitis
  • Inflammation

Keywords

  • Pregnancy outcome
  • Feasibility
  • Milk Fortification
  • Periodontitis
  • Pregnant women
  • Periodontal Therapy
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 year;
  • Up to 16 weeks' gestation;
  • Having ≥ 20 teeth;
  • Diagnosis of periodontitis (≥ 1 tooth with at least one of periodontal sites with ≥ 4 mm of clinical attachment loss and bleeding on probing on the same site);
  • Not received regular dental treatment in the last 6 months (except from those who only visited the dentist for an emergency appointment e.g. tooth extraction);
  • Cognitively and physically able to complete an interview and oral examination; and
  • Willing to participate (including provision of blood samples)

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of /AIDS, psychosis, diabetes before pregnancy, thyroid disease, or disorders causing vitamin D (e.g. sarcoidosis and other lymphomatous disorders);
  • Diagnosis of lactose intolerance or milk allergy;
  • History of renal stones or family history of renal stone and hyperparathyroidism;
  • presence of extensive dental cavity and decay;
  • Use of antibiotics or any immune-suppressants or medication known to affect vitamin D/calcium metabolism; and
  • Consumption of ≥4 servings/day of dairy products or taking vitamin D supplements at > 400 IU/day.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Early PT plus Fortified Milk

    early periodontal therapy (during pregnancy) plus fortified milk

    Other: Early PT · Dietary Supplement: Fortified Milk

  • Experimental
    Early PT plus Plain Milk

    early periodontal therapy (during pregnancy) plus plain milk

    Other: Early PT · Dietary Supplement: Plain Milk

  • Experimental
    Delayed PT plus Fortified Milk

    delayed periodontal therapy (after delivery) plus fortified milk

    Other: Delayed PT · Dietary Supplement: Fortified Milk

  • Placebo comparator
    Delayed PT plus Plain Milk

    delayed periodontal therapy (after delivery) plus plain milk

    Other: Delayed PT · Dietary Supplement: Plain Milk

Interventions

  • OtherEarly PT

    Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery

    Also known as: Early non-surgical periodontal therapy

  • OtherDelayed PT

    Women will receive conventional non-surgical PT delayed until after delivery.

    Also known as: Delayed non-surgical periodontal therapy

  • Dietary supplementFortified Milk

    participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.

  • Dietary supplementPlain Milk

    Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).

    Also known as: non-fortified milk (placebo)

06

What researchers measure

Primary outcomes

  1. Feasibility (acceptability of study design, recruitment strategy, random allocation and data collection procedures)

    Feasibility will be evaluated using mixed-methods to explore intervention delivery, participants' acceptability, challenges and issues faced during the study, and recommended changes to the study design. Focus groups discussions will be held prior to trial recruitment to discuss issues regarding recruitment strategy, study design and data collection. In addition, group discussions will be held throughout the study (2nd and 3rd trimester) to assess potential barriers and facilitators to the intervention and data collection. At the end of each participant's involvement in the study, the participant will be asked to complete an anonymous, acceptability questionnaire to gain insights about participant's reactions to research participation and how acceptable the participant found study requirements and assessments were.

    Time frame: From baseline till 6-8 weeks' postpartum

  2. Recruitment rate

    This will be measured by the total number of participants recruited into the study. The investigators intend to recruit 120 participants. Recruitment rate will be calculated (number of participants per month)

    Time frame: one year

  3. Adherence

    number of drop-outs in each study arm. Analyses of drop-out rates (%) in four study arms. Self-reported quantity of milk consumed during the study. Number of follow-up visits. Proportion of participants who provide full data at baseline, throughout pregnancy and up to 6-8 weeks postpartum.

    Time frame: From baseline till 6-8 weeks' postpartum

Secondary outcomes

  1. Changes in % of sites with bleeding on probing

    Certified and calibrated dentists will conduct dental examinations pre/post-intervention. Full mouth periodontal examination will be performed at six sites per tooth, using disposable periodontal probes with coloured-coded area and mirror but without X-rays. Bleeding scores will be determined as percentage of sites with bleeding relative to the total number of sites examined.

    Time frame: baseline and 6-8 weeks' postpartum

  2. Changes in maternal blood biomarkers to assess inflammation

    Blood samples will be taken to assess changes in cytokines levels: CRP, IL-6 and MMP-9.

    Time frame: 10 months on average

  3. Changes in maternal serum levels of 25(OH)D

    Blood samples will be taken to assess changes in 25(OH)D levels

    Time frame: 10 months on average

  4. Changes in maternal glucose levels

    Fasting blood samples will be taken to assess changes in glucose levels

    Time frame: 10 months on

  5. Changes in maternal insulin levels

    Fasting blood samples will be taken to assess changes in insulin levels

    Time frame: 10 months on average

  6. Changes in maternal serum levels of calcium

    Fasting blood samples will be taken to assess changes in calcium levels

    Time frame: 10 months on average

  7. Changes in maternal blood lipids levels

    Fasting blood samples will be taken to assess changes in total cholesterol and HDL-c

    Time frame: 10 months on average

  8. Neonatal levels of 25(OH)D

    drops of neonatal capillary blood will be collected via heel prick (200 μl) for measurement of 25(OH)D concentrations at the routine neonatal check-up

    Time frame: between 8 to 22 months

  9. Neonatal levels of calcium

    drops of neonatal capillary blood will be collected via heel prick (200 μl) for measurement of calcium concentrations

    Time frame: between 8 to 22 months

07

Study locations

1 site
  • Centro Municipal de Saúde de Duque de Caxias & Policlínica Hospital Duque de Caxias
    Rio de Janeiro, Brazil
08

References and documents

Publications

  • Rodrigues Amorim Adegboye A, Cocate PG, Benaim C, da Veiga Soares Carvalho MC, Schlussel MM, de Castro MBT, Kac G, Heitmann BL. Recruitment of low-income pregnant women into a dietary and dental care intervention: lessons from a feasibility trial. Trials. 2020 Mar 5;21(1):244. doi: 10.1186/s13063-020-4142-5. PubMed 32138765 ↗
  • Cocate PG, Kac G, Heitmann BL, Nadanovsky P, da Veiga Soares Carvalho MC, Benaim C, Schlussel MM, de Castro MBT, Alves-Santos NH, Baptista AF, Holick MF, Mokhtar RR, Bomfim AR, Adegboye ARA. Calcium and vitamin D supplementation and/or periodontal therapy in the treatment of periodontitis among Brazilian pregnant women: protocol of a feasibility randomised controlled trial (the IMPROVE trial). Pilot Feasibility Stud. 2019 Mar 5;5:38. doi: 10.1186/s40814-019-0417-6. eCollection 2019. Erratum In: Pilot Feasibility Stud. 2020 Nov 27;6(1):187. doi: 10.1186/s40814-020-00727-6. PubMed 30873290 ↗

Individual participant data

Plan to share: Undecided — External users will be bound by a data sharing agreement (in Portuguese and English) which will be available as part of the application to share data on the University website

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in May 2018, 13 months.

Of 484 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's 13 months is below that.

Counting every sponsor, half of 498 studies reached it within 15 months; a quarter within 8 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2016
First posted
May 11, 2017
StartActual
Apr 24, 2017
Primary completionActual
May 30, 2018
CompletionActual
May 30, 2018
Last update
Aug 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03148483
Lead sponsor
University of Westminster
Collaborators
Universidade Federal do Rio de Janeiro, Copenhagen University Hospital, Denmark, Rio de Janeiro State University, Instituto Fernandes Figueira, University of Oxford, Boston University
Responsible party
Amanda Rodrigues Amorim Adegboye (Senior Lecturer, Principal Investigator, University of Westminster) — Principal investigator
First posted
May 11, 2017
Start date
Apr 24, 2017
Primary completion
May 30, 2018
Completion
May 30, 2018
Last update
Aug 3, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion